Announcement of major shareholder crescent capitals exit

Australian Clinical Labs Limited (ASX: ACL) has announced that Crescent Capital, a major shareholder holding a 30.12% stake, has sold its entire shareholding in a block trade. ACL stated it has no further information at this time and the announcement was authorised by the company's Disclosure Committee.

ACL is a leading Australian private provider of pathology services, operating 76 NATA-accredited laboratories that perform a diverse range of tests for various clients, including doctors, specialists, patients, hospitals and corporate clients. The company is focused on combining talented people, medical and scientific leadership, innovative thinking and technologies to empower decision-making that saves and improves patients' lives. The sale of Crescent Capital's significant shareholding marks a major change in ACL's ownership structure.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com